EUVIMEDEUVIMED entdecken
Crossref

Urinary Calprotectin Is Not a Reliable Surrogate of Fecal Calprotectin Levels in Adults and Children with Crohn’s Disease

Bernadette White, Linda Varcamonti, Konstantinos Gkikas, Caroline Kerbiriou, John-Paul Seenan, Jonathan Macdonald, Richard Hansen, Richard K Russell, Konstantinos Gerasimidis

Digestive Diseases and Sciences · 2026

DOI: 10.1007/s10620-026-09795-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive Diseases and Sciences, 2026. Verfasst von Bernadette White und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Nutrition, College of Medical, Veterinary, and Life Sciences, University of Glasgow, New Lister Building, Glasgow Royal Infirmary…. Hauptthemen laut MEDLINE: Leukocyte L1 Antigen Complex, Crohn Disease, Feces. Die Arbeit nennt 22 Literaturangaben. Gefördert von: Nestle Health Science, Leona M. and Harry B. Helmsley Charitable Trust, Jon Moulton Charity Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Fecal calprotectin (FCAL) is an established biomarker for monitoring intestinal inflammation in inflammatory bowel disease. However, fecal sampling can be socially unacceptable and inconvenient. Urinary calprotectin (UCAL) could potentially be a suitable surrogate marker of FCAL. METHODS: Levels of FCAL and UCAL and C-reactive protein (CRP) were measured in samples from two different cohorts; a) in adults with active Crohn's disease (CD) receiving induction treatment with adalimumab and b) children with CD during early food re-introduction after successful treatment with exclusive enteral nutrition (EEN). In each cohort, participants were categorized based on their FCAL trajectories. Adults were classified as responders if FCAL decreased ≥ 50% after 12 weeks of treatment; otherwise, they were classified as non-responders. In children, a FCAL baseline rise > 100% during three weeks of food reintroduction, after EEN, was classified as having an FCAL increase. Children were classified as FCAL-stable if FCAL remained < 300 mg/kg throughout food reintroduction. FCAL, UCAL and CRP were also measured in healthy adults. RESULTS: A total of 364 paired stool and urine samples, and 100 blood samples were utilized from adults and children with CD. Changes in UCAL did not parallel changes in FCAL, neither in adults who were classed as FCAL responders after 12-weeks treatment with biologics, nor in pediatric patients who demonstrated an increase in FCAL, following completion of EEN and return to normal diet. UCAL did not correlate with either FCAL or CRP. CONCLUSIONS: Urinary calprotectin is not a useful biomarker of systemic or gut inflammation in patients with CD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukocyte L1 Antigen ComplexCrohn DiseaseFecesHumansBiomarkersFemaleAdultMaleChildAdolescentC-Reactive ProteinYoung AdultAdalimumabMiddle AgedEnteral Nutrition

Stichwörter der Autor:innen

CalprotectinCrohn’s diseaseFecesStoolUrine

Substanzen

Leukocyte L1 Antigen ComplexBiomarkersC-Reactive ProteinAdalimumab

Autor:innen und Institutionen

  • Department of Human Nutrition, College of Medical, Veterinary, and Life Sciences, University of Glasgow, New Lister Building, Glasgow Royal Infirmary, Glasgow, G31 2ER, UK.
  • Department of Translational Medical Science, Section of Pediatrics, University of Naples Federico II, Naples, Italy.
  • Department of Gastroenterology, Elizabeth University Hospital, Glasgow, Queen, UK.
  • Division of Clinical and Molecular Medicine, School of Medicine, University of Dundee, Dundee, UK.
  • Department of Paediatric Gastroenterology, Royal Hospital for Children & Young People, Edinburgh, UK.
  • Department of Human Nutrition, College of Medical, Veterinary, and Life Sciences, University of Glasgow, New Lister Building, Glasgow Royal Infirmary, Glasgow, G31 2ER, UK. Konstantinos.gerasimidis@glasgow.ac.uk.

Förderung

  • Nestle Health Science
  • Leona M. and Harry B. Helmsley Charitable Trust
  • Jon Moulton Charity Trust

Zitieren

APA

White, B., Varcamonti, L., Gkikas, K., Kerbiriou, C., Seenan, J. P., Macdonald, J., Hansen, R., Russell, R. K., & Gerasimidis, K. (2026). Urinary Calprotectin Is Not a Reliable Surrogate of Fecal Calprotectin Levels in Adults and Children with Crohn’s Disease. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-026-09795-9

Vancouver

White B, Varcamonti L, Gkikas K, Kerbiriou C, Seenan JP, Macdonald J, et al. Urinary Calprotectin Is Not a Reliable Surrogate of Fecal Calprotectin Levels in Adults and Children with Crohn’s Disease. Digestive Diseases and Sciences. 2026. doi:10.1007/s10620-026-09795-9

BibTeX
@article{White2026,
  author = {White, Bernadette and Varcamonti, Linda and Gkikas, Konstantinos and Kerbiriou, Caroline and Seenan, John-Paul and Macdonald, Jonathan and Hansen, Richard and Russell, Richard K and Gerasimidis, Konstantinos},
  title = {Urinary Calprotectin Is Not a Reliable Surrogate of Fecal Calprotectin Levels in Adults and Children with Crohn’s Disease},
  journal = {Digestive Diseases and Sciences},
  year = {2026},
  doi = {10.1007/s10620-026-09795-9}
}
Kostenlos starten →